ATE153695T1 - Verfahren zur herstellung von antikörpern - Google Patents

Verfahren zur herstellung von antikörpern

Info

Publication number
ATE153695T1
ATE153695T1 AT91203080T AT91203080T ATE153695T1 AT E153695 T1 ATE153695 T1 AT E153695T1 AT 91203080 T AT91203080 T AT 91203080T AT 91203080 T AT91203080 T AT 91203080T AT E153695 T1 ATE153695 T1 AT E153695T1
Authority
AT
Austria
Prior art keywords
lymphocytes
producing antibodies
antibodies
immortalized
preceded
Prior art date
Application number
AT91203080T
Other languages
English (en)
Inventor
Petrus Gerardus A Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE153695T1 publication Critical patent/ATE153695T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT91203080T 1990-11-26 1991-11-25 Verfahren zur herstellung von antikörpern ATE153695T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203124 1990-11-26

Publications (1)

Publication Number Publication Date
ATE153695T1 true ATE153695T1 (de) 1997-06-15

Family

ID=8205174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91203080T ATE153695T1 (de) 1990-11-26 1991-11-25 Verfahren zur herstellung von antikörpern

Country Status (12)

Country Link
EP (1) EP0488470B1 (de)
JP (1) JP3392883B2 (de)
KR (1) KR100223381B1 (de)
AT (1) ATE153695T1 (de)
AU (1) AU646108B2 (de)
CA (1) CA2056102C (de)
DE (1) DE69126281T2 (de)
DK (1) DK0488470T3 (de)
ES (1) ES2103770T3 (de)
GR (1) GR3024487T3 (de)
NZ (1) NZ240748A (de)
ZA (1) ZA919299B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474755A (en) * 1984-01-31 1995-12-12 Akzo Nobel N.V. Tumor associated monoclonal antibodies
EP0650735A3 (de) * 1993-07-09 1999-04-14 Akzo Nobel N.V. Kit und Verfahren zum Vorziehen
EP0693121A4 (de) * 1994-02-04 1999-11-03 Akzo Nobel Nv Monoklonaler antikörper 88bv59, subklone und herstellungsverfahren
ZA9710391B (en) * 1996-12-06 1998-06-23 Akzo Nobel Nv Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent.
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them
US7037663B2 (en) 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
BR9908096A (pt) 1998-02-19 2000-10-31 Eastern Virginia Med School Proteìna 3 da zona pelúcida humana (hzp3), ativa, recombinante
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
SE0002835D0 (sv) * 2000-08-07 2000-08-07 Karolinska Innovations Ab Method and kit for production of monoclonal antibodies
AU9373501A (en) 2000-08-14 2002-02-25 Akzo Nobel Nv Use of antibodies against specific mhc-peptide complexes
CA2456821A1 (en) 2001-08-02 2003-02-13 Trinity Biomedical Technology Corporation Human zona pellucida proteins and methods of their use in diagnosing male infertility
JP3799392B2 (ja) * 2003-03-28 2006-07-19 財団法人富山県新世紀産業機構 １個の抗原特異的ｂリンパ球を用いた抗原特異的抗体産生ハイブリドーマの作製方法及びモノクローナル抗体の製造方法
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005019823A1 (en) * 2003-08-20 2005-03-03 Celltech R & D Limited Methods for obtaining antibodies
US7807415B2 (en) 2005-08-23 2010-10-05 Iq Therapeutics Bv Methods of producing stable B-lymphocytes
CN101600793B (zh) * 2006-05-19 2013-06-26 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
PL2164514T3 (pl) 2007-05-21 2017-08-31 Alderbio Holdings Llc Przeciwciała przeciwko IL-6 i ich zastosowanie
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
KR20120118088A (ko) 2009-11-24 2012-10-25 앨더바이오 홀딩스 엘엘씨 Ⅰｌ-6에 대한 항체 및 이들의 용도
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
AU2011332817A1 (en) 2010-11-23 2013-06-13 Alder Biopharmaceuticals, Inc. Anti-IL-6 antibodies for the treatment of anemia
EP3363812A1 (de) 2011-06-23 2018-08-22 Ablynx NV Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
CN108659121A (zh) 2011-06-23 2018-10-16 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
EP4350345A2 (de) 2011-06-23 2024-04-10 Ablynx N.V. Verfahren zur vorhersage, erkennung und reduzierung von aspezifischer proteininterferenz in tests mit variablen immunglobulin-einzeldomänen
EP2727942A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
EP2727943A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
EP2914629A1 (de) 2012-11-05 2015-09-09 MAB Discovery GmbH Verfahren zur herstellung multispezifischer antikörper
US20160033504A1 (en) * 2013-03-15 2016-02-04 Alder Biopharmaceuticals, Inc. Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
EP4273232A3 (de) 2016-03-30 2024-01-03 F. Hoffmann-La Roche AG Verfahren zur kultivierung von b-zellen
EP3241845A1 (de) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanisierte anti-il-1r3-antikörper
WO2018122147A1 (en) 2017-01-02 2018-07-05 F. Hoffmann-La Roche Ag B-cell cultivation method
EP3401332A1 (de) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antikörper zur verwendung bei entzündungskrankheiten
CN110621773B (zh) 2017-05-19 2023-06-09 豪夫迈·罗氏有限公司 用于产生胸腺细胞上清液的方法
EP3717632B1 (de) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG Verfahren zur kultivierung von b-zellen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054687A (ja) * 1983-07-19 1985-03-29 スロ−ン−ケツタリング　インステイテユ−ト　フオ−　キヤンサ−　リサ−チ ヒト　モノクロ−ン抗体の製法
US4797473A (en) * 1986-06-25 1989-01-10 Regents Of The University Of Minnesota Monoclonal antibodies to unreduced, nonenzymatically-glycated proteins
DE4107765A1 (de) * 1990-07-28 1992-01-30 Schebo Tech Medizinisch Biolog Pankreas-elastase-1-spezifischer antikoerper, ein verfahren zu seiner gewinnung und ein testkit der solche antikoerper enthaelt

Also Published As

Publication number Publication date
CA2056102C (en) 2003-03-25
DK0488470T3 (da) 1997-12-22
AU8817391A (en) 1992-08-20
EP0488470A1 (de) 1992-06-03
JP3392883B2 (ja) 2003-03-31
CA2056102A1 (en) 1992-05-27
JPH0576383A (ja) 1993-03-30
AU646108B2 (en) 1994-02-10
DE69126281D1 (de) 1997-07-03
DE69126281T2 (de) 1997-10-16
KR100223381B1 (ko) 1999-10-15
NZ240748A (en) 1996-12-20
EP0488470B1 (de) 1997-05-28
GR3024487T3 (en) 1997-11-28
KR920009987A (ko) 1992-06-26
ZA919299B (en) 1992-08-26
ES2103770T3 (es) 1997-10-01

Similar Documents

Publication Publication Date Title
ATE153695T1 (de) Verfahren zur herstellung von antikörpern
DE3587360D1 (de) Verfahren zur herstellung von chimaerischen monoklonalen antikoerpern.
ATE153332T1 (de) Verfahren zur herstellung von oxetanonen
DE122004000017I1 (de) Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.
DE59101695D1 (de) Verfahren zur Erzeugung von niederen Olefinen.
DE69429095T2 (de) Humanisierte antikoerper
DE69116921D1 (de) Verfahren zur Reinigung von monoklonalen Antikörpern
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
DE69132562D1 (de) Verfahren zur automatischen Erzeugung von partiellen, differentialen Gleichungen zur Simulation
ATE187176T1 (de) Verfahren zur herstellung von heterologen bispezifischen antikörpern
DE69112459D1 (de) Verfahren zur Herstellung von Sulfidphosphor.
DE3775618D1 (de) Verfahren zur herstellung von toner durch suspensionspolymerisation.
DE69003897D1 (de) Verfahren zur herstellung von kohlenwasserstoffaminen.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
ATE101144T1 (de) Verfahren zur herstellung von cyclischen sulfaten.
DE69513847D1 (de) Verfahren zur herstellung von substituierten 3-aminobenzonitrilen
ATE172446T1 (de) Verfahren zur herstellung von radiomarkierten meta-halobenzylguanidin
DE59303813D1 (de) Verfahren zur Herstellung von Germaniumdihalogenid-Ether-Addukten
ATE173504T1 (de) Granulozytenbindende antikörperkonstrukte, ihre herstellung und verwendung
DE59200623D1 (de) Verfahren zur Herstellung von Chromleder.
DE3576177D1 (de) Verfahren zur herstellung von synthesefasern.
DE69122169D1 (de) Verfahren zur Herstellung von Tonern
DE59102853D1 (de) Verfahren zur herstellung mikromechanischer strukturen.
NO962125D0 (no) Anti-idiotypiske antistoffer som induserer en immunrespons mot epidermal vekstfaktorreseptor
ATE256104T1 (de) Verfahren zur herstellung von indan-ähnlichen verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time